➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
Mallinckrodt
Moodys
Boehringer Ingelheim
Medtronic

Last Updated: October 26, 2020

DrugPatentWatch Database Preview

Patent: 9,175,009

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,175,009
Title:Benzoxepin PI3K inhibitor compounds and methods of use
Abstract: Benzoxepin compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z.sup.1 is CR.sup.1 or N; Z.sup.2 is CR.sup.2 or N; Z.sup.3 is CR.sup.3 or N; Z.sup.4 is CR.sup.4 or N; and where (i) X.sup.1 is N and X.sup.2 is S, (ii) X.sup.1 is S and X.sup.2 is N, (iii) X.sup.1 is CR.sup.7 and X.sup.2 is S, (iv) X.sup.1 is S and X.sup.2 is CR.sup.7; (v) X.sup.1 is NR.sup.8 and X.sup.2 is N, (vi) X.sup.1 is N and X.sup.2 is NR.sup.8, (vii) X.sup.1 is CR.sup.7 and X.sup.2 is O, (viii) X.sup.1 is O and X.sup.2 is CR.sup.7, (ix) X.sup.1 is CR.sup.7 and X.sup.2 is C(R.sup.7).sub.2, (x) X.sup.1 is C(R.sup.7).sub.2 and X.sup.2 is CR.sup.7; (xi) X.sup.1 is N and X.sup.2 is O, or (xii) X.sup.1 is O and X.sup.2 is N, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. ##STR00001##
Inventor(s): Blaquiere; Nicole (San Francisco, CA), Do; Steven (San Jose, CA), Dudley; Danette (Pacifica, CA), Folkes; Adrian (Berkshire, GB), Goldsmith; Richard (Belmont, CA), Heald; Robert (Harlow, GB), Heffron; Timothy (Burlingame, CA), Kolesnikov; Aleksandr (San Francisco, CA), Ndubaku; Chudi (San Francisco, CA), Olivero; Alan G. (Half Moon Bay, CA), Price; Stephen (Harlow, GB), Staben; Steven (San Francisco, CA), Wei; BinQing (Belmont, CA)
Assignee: GENENTECH, INC. (South San Francisco, CA)
Application Number:14/565,669
Patent Claims:see list of patent claims

Details for Patent 9,175,009

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech LUCENTIS ranibizumab INJECTABLE; INJECTION 125156 001 2006-06-30   Start Trial GENENTECH, INC. (South San Francisco, CA) 2039-02-26 RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial GENENTECH, INC. (South San Francisco, CA) 2039-02-26 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial GENENTECH, INC. (South San Francisco, CA) 2039-02-26 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 9,175,009

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
Moodys
Dow
Express Scripts
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.